CELLINK's founders informs about executing a call option

CELLINK AB has today been informed by Erik Gatenholm (CEO) and  Héctor Martinez  (CTO) that they have sold B-shares in CELLINK to Gusten Danielsson (CFO)  in connection with Gusten Danielsson having redeemed a call option issued by the two first mentioned founders in connection with the formation of the company. The purchase has been made to equal parts from the first two founders for quota value and the total number of shares (760,000) corresponds to approximately 1.8% of the outstanding shares in the company.

After the transaction, Erik Gatenholm owns 10,476,160 shares, Héctor Martinez owns 6,814,160 shares and Gusten Danielsson owns 1,551,732 shares in the company.

For further information, please contact:

Erik Gatenholm, CEO                                                              Gusten Danielsson, CFO

Phone (Sweden): +46 73 267 00 00                                         Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (650) 515 5566                                                Phone (US): +1 (857) 332 2138

E-mail: [email protected]                                                             E-mail: [email protected]

About CELLINK

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK B. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected]

Latest press releases
March 22, 2020RegulatoryUpdate regarding COVID-19
November 14, 2019Annual Report 2018/2019